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Chronic renal allograft rejection can be predicted by area under
the serum creatinine versus time curve (AUCCr)
SERDAR YILMAz, AsLI YILMAZ, and PEKI HAYRY
Transplantation Laborato,y, University of Helsinki, Helsinki, Finland
Chronic renal allograft rejection can be predicted by area under the
serum creatinine versus time curve (AUCCr). Acute rejection is the most
important single risk factor for chronic renal allograft rejection. Numerical
quantitation of rejection episodes does not take into account the intensity
and length of these episodes, both of which may contribute to the severity
of chronic rejection. We propose a single numerical parameter for the
frequency, intensity and length of acute rejections, the "Area Under the
Serum Creatinine versus Time Curve" (AUCCr) using renal allografts
between inbred rat strains. Twenty-seven renal transplantations were
performed from the DA to WE rat strain. The rats were immunosup-
pressed with 5 mg/kg body weight of CyA injected s.c. for 1, 2, 3 and 12
weeks, resulting in differing numbers (0—4) of biopsy-confirmed acute
rejections of varying intensity (s-cre: 100—448 jsmol/L) and length (3—24
days), all of which were reversed with additional CyA treatment. The
intensity of chronic changes in graft histology was quantitated using the
"Chronic Allograft Damage Index" (CADI). End-point transplant func-
tion was quantitated as level of serum creatinine at sacrifice. The AUCCr
from 0 to 3 weeks (AUCcr03), encompassing the recovery period after
operation, free of rejections, did not correlate with the CAD! (r 0.230,
P = 0.249). All AUCC. from 3 weeks onwards correlated with the CADI.
The best correlation with the CADI was obtained with AUCcr from 3 to
12 weeks (AUCcr312) (r = 0.922, P = 0.0001). This interval coincides
with the timing of all acute rejection episodes. AUCr312 correlated
equally well to end-point transplant function (r = 0.890, P = 0.0001). The
correlations of AUCcr312 to CADI and to end-point transplant function
were better than the correlations of the number of acute rejections (r =
0.876, P = 0.0001) and (r = 0.811, P = 0.0001), respectively, indicating
that AUCr312 is a more sensitive parameter than the number of acute
rejections for predicting chronic rejection. Our results also indicate that
there is a causal relationship between acute and chronic rejection, and that
not only the frequency but also the intensity and length of acute rejections
contribute. Reduction in the number of acute rejection episodes as well as
minimizing their intensity with aggressive immunosuppressive therapy will
both contribute to the reduction of chronic rejection.
Chronic rejection is the major reason for the late loss of an
allograft. In a recent consensus conference on chronic rejection
(Fourth Alexis Carrel Conference, Kiruna, Sweden) [1], chronic
renal allograft rejection was defined as "gradual deterioration in
graft function (at least over a 3 month interval, after 3 months
post-transplantation) in the absence of any other disease and
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necessary graft histology to confirm the diagnosis." Transplant
deterioration is usually quantitated as a decline in calculated
creatinine clearance and/or an increase in the level of serum
creatinine [2].
In another consensus conference (Banif classification of kidney
transplant pathology) [31 agreement was reached on an interna-
tionally standardized criteria for renal allograft histology. The
histological alterations of chronic rejection, agreed upon in the
conference, were the same as suggested 40 years ago by Hume et
a! [4] and Porter et al [5], that is, persistent interstitial inflamma-
tion and fibrosis, glomerular mesangial matrix increase and scle-
rosis, vascular intimal proliferation and thickening, and tubular
atrophy. We have recently shown that the histological alterations
of chronic rejection may be quantitated and expressed as a single
numerical figure, "The Chronic Allograft Damage Index" (CAD!)
[6]. In human renal allografts, incipient histological changes of
chronic rejection, as quantitated with CAD! at two years post-
transplant are highly predictive to subsequent clinical chronic
rejection at six years (r = 0.717, P = 0.0001) [7].
Risk factors leading to chronic renal allograft rejection focus
largely on the perioperative period and the first post-transplant
year. Acute rejection is probably the most important single risk
factor for chronic rejection [8—11]. In addition, the following
parameters may also contribute to rejection: histoincompatibility
[12—14], preservation time [15—18], donor and recipient age
[19—211, hyperlipidemia [22] and inadequate immunosuppression
[8].
The frequency (or number) of acute rejection episodes [8—11]
as a numerical parameter for chronic rejection does not take into
account the intensity of and/or the length of the episodes, neither
does it take into account whether the episodes have been com-
pletely treated and the transplant has been returned to optimal
level of function. In this study we investigated, under controlled
laboratory conditions, whether and to what extent the intensity
and length of acute rejection episodes contribute to the develop-
ment of chronic renal allograft rejection. Using rat renal trans-
plants with differing levels of immunosuppression and varying
frequencies and intensities of acute rejection episodes, we dem-
onstrated that the "area under the serum creatinine versus time
curve" (AUCr) correlates better than the number of acute
rejection episodes both to the CADI and to late graft function.
Furthermore, we established a causal relationship between acute
and chronic rejection, suggesting that the AUCr may be used as
an early predictive parameter for chronic renal allograft rejection.
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Methods
Animals
Male inbred WF (RT1U) and DA (RT1) rats weighing 250 to
300 g and two to three months of age were used for transplanta-
tion. The animals were purchased from The Laboratory Animal
Centre, University of Helsinki, Helsinki, Finland. They were fed
with regular rat food (altromin, Standart Dioet, Chr. Petersen
A'S, Ringsted, Denmark), and tap water ad libitum and main-
tained on a 12 hour light/dark cycle. The animals received humane
care in compliance with the "Principles of Laboratory Animal
Care" and the "Guide for the Care and Use of Laboratory Animal
Resources" published by the National Institutes of Health (NIH
Publication No. 86—23, revised 1985).
Transplantations
Kidney transplants were performed from the DA to the WF
strain using a modified technique of Fisher and Lee [23]. The
donor kidney was transplanted heterotopically by end-to-side
anastomosis of donor renal artery and recipient aorta, donor renal
vein and recipient inferior vena cava below the left renal artery
under intraperitoneal chloral hydrate anaesthesia. Ureteral anas-
tomosis was performed end-to-end close to the renal pelvis. The
right native kidney was removed during transplantation. Left
nephrectomy was delayed for seven days to allow recovery from
acute tubular necrosis of the transplanted kidney. Buprenorphi-
num was used for postoperative pain relief (Temgesic, Reckitt &
Colman, Hull, UK). Total perioperative ischemia time was stan-
dardized between 25 and 30 minutes, beginning with exangui-
nation and cold perfusion of the graft, and ending with revascu-
larization of the graft.
Medication
The recipient rats were divided in four groups. Cyclosporine
(CsA; Sandimmun, Sandoz, Basle, Switzerland) at a concentration
of 50 mg/ml was dissolved in intralipid (Kabi Vitrum, Stockholm,
Sweden) and administered subcutaneously once a day. Subcuta-
neous administration of CsA was begun immediately after com-
pletion of the operation using a dose of 5 mg/kg of body weight for
12 (N = 5), 3 (N = 7), 2 (N = 7) and 1 (N = 8) weeks.
Follow-up
The diagnosis of acute allograft rejection was made if there was
a rise in serum creatinine to over 200 jmol/liter during or more
than seven days after the last drug administration and if other
causes were excluded. On such occasions, additional CsA was
given s.c. at a dose of 5 mg/kg of body weight during the period
when serum creatinine stayed over 200 jimol/liter to counteract
acute rejection. The first rejection episode was always verified by
core needle biopsy taken with a Biopty instrument (Radioplast,
Uppsala, Sweden) with a 18 G Biopty-Cut needle. The needle was
placed parallel to the long axis of the graft and two cores of tissue
were obtained. No grafts were lost due the biopsy.
Serum creatinine and CsA concentrations were measured twice
a week, until the rats were sacrificed. Blood was drawn from the
tail tip.
Definition of chronic rejection
Chronic renal allograft rejection was defined according to the
recent consensus conference on chronic rejection [1]. In this study
we applied these criteria to the rat. In addition to the descriptive
histopathologic diagnosis of chronic rejection, we quantitated
biopsy histology to determine the intensity of histological changes
of chronic rejection [6, 24].
Quantitation of histopathology
The grafts were harvested 12 weeks after transplantation. They
were bisected horizontally and fixed in 10% buffered formalin.
The specimens were examined histologically following sectioning
and staining with hematoxylin-eosin, Masson's trichrome, periodic
acid-Schiff and methyl-green-pyronin. For each specimen, 31
histologic features [241 were evaluated and scored blindly by two
independent investigators using an arbitrary scale from 0 to 3, 0
indicating no pathological alterations and 3 extreme changes. The
final score was reached by consensus agreement. The "Chronic
Allograft Damage Index" (CADI) [6] was calculated from the
sum of inflammation and fibrosis in interstitium, mesangial matrix
increase and sclerosis of glomeruli, intimal proliferation of vessels
and tubular atrophy. The CAD! is expressed as a single numerical
figure to show the intensity of chronic changes in the transplant.
A UC,. calculation
Area under the postoperative serum creatinine versus time
curve (AUCCr) over 100 mol/liter of serum creatinine was
calculated using a Microsoft Excel (Microsoft Corporation, Red-
mond, WA, USA) program.
Statistics
Statistical analyzes including linear regression and the Mann-
Whitney U-test were performed using the StatView statistical
package (Abacus Concepts, Inc., Berkeley, CA, USA). The results
are expressed as the mean SD, and a probability of < 0.05 was
accepted as significant.
Results
The clinical course
Renal transplants were performed from the DA to the WF
strain of rats and they were immunosuppressed with 5 mg/kg/day
s.c. of CsA. We have previously [24] demonstrated that this level
of immunosuppression brings CsA to the level of 1250 mg/liter in
seven days, where it then stabilizes.
The rats were divided into four groups according to the length
of immunosuppression: the first group (N 5) received CsA for
12 weeks, the second (N = 7) for 3 weeks, the third (N = 7) for
2 weeks and the fourth (N = 8) for 1 week. After discontinuing of
CsA the blood CsA levels returned to zero within two to three
days.
Serum creatinine determinations were performed on alternate
days. When the serum creatinine (SCr) rose above 200 mmol/liter,
a core needle biopsy was performed and additional CsA at a dose
of 5 mg/kg/day was administered until the serum creatinine level
fell below 200 mmol/liter; on most occasions it returned to
normal. The acute rejection episodes were of different intensities
(Scr 100 mmol/liter to 448 mmol/liter) and length (3 to 24 days).
All early elevations in serum creatinine at this time period
coincided with biopsy histology consistent with acute rejection
[25].
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The clinical course of eight representative recipient rats is given
in Figure 1, where serum creatinine and duration of immunosup-
pression are depicted. Despite the fact that inbred animals were
used as donors and recipients and that the same dose of immu-
nosuppression was used, the clinical course was astonishingly
variable. The postoperative downward slope of the serum creati-
nine was more or less uniform in these rats; however, the animals
experienced none to several rejection episodes. In addition the
intensity and length of rejection episodes was variable.
Regardless of the variation between individual rats, the length
of immunosuppressive treatment still correlated significantly with
the frequency of acute rejection episodes within each group: there
were no rejection episodes in the group receiving 12-week immu-
nosuppression, on the average one rejection episode per rat in the
3-week treatment group, 2.3 rejections per rat in the 2-week
treatment group and 2.6 rejections per rat in the 1-week treatment
group (data not shown).
The largest cumulative dose of CsA per rat, which was 84
mg/kg, was observed in the 12-week treatment group. In the
groups receiving 1-, 2-, and 3-week treatments, the total CsA dose
was approximately about 1/3 of the above. Because each individ-
ual acute rejection episode was treated by CsA, the total cumu-
lative dose of CsA in the remaining three groups (1-, 2-, and
3-weeks) was the same: 32 8, 33 12, and 30 11 mg/kg body
wt (P = NS), respectively. As the adequacy of immunosuppressiorl
will be the subject of a separate report, it will not be commented
further on in this communication.
To quantitate the intensity of chronic rejection, we used the
quantitative histological CADI and end-point transplant function
(serum creatinine). The Chronic Allograft Damage Index, CAD!,
at sacrifice almost linearly correlated to end-point transplant
function (r = 0.874, P = 0.0001) as depicted in Figure 2.
Correlation of A UC to CADI
The best correlation of the AUCCr to the CAD! was deter-
mined by calculating the AUCCr over different postoperative time
periods, and by quantitating the significance of regression. This is
shown in Table 1,
If we calculated the AUCCr throughout most of observation
period, from 0 to 12 weeks (AUCr012), correlation to the
CADI was highly significant (r = 0.877, r2 = 0.769, P = 0.0001).
If we calculated only the initial time period from 0 to 3 weeks
(AUCcrO3), which encompasses primarily the recovery period
from operation with no or very few rejections, the correlation was
not significant (r = 0.230, r2 = 0.053, P = 0.249; Fig. 3a).
We considered this observation to reflect the fact that the
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Fig. 1. Clinical course of 8 representative recipient rats where the serum creatinine (pmollliter; solid line) and the duration of immunosuppression (shaded
bars on the horizontal axis) are depicted. Acute rejection episodes are indicated as 10, 2°, etc. Animals in (a) and (b) received 5 mg/kg/day of CsA for basic
immunosuppression for 12 weeks, in (c) and (d) for 3 weeks, in (e) and (f) for 2 weeks, and in (g) and (h) for 1 week. Additional CsA given for rejection
is also shown in (c), (d), (e), (f), (g) and (h) (animals in the 12-week treatment group had no rejection episodes).
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operative procedure and the subsequent recovery period were
well standardized and homogeneous among this population of
animals, and that the high correlation observed between the
Fig. 1. Continued.
.Time period
of AUCCr
Correlation coefficient
P valuer r2
0—12 weeks 0.877 0.769 0.0001
0—3 weeks 0.230 0.053 0.249
3—8 weeks 0.748 0.560 0.0001
8—12 weeks 0.889 0.791 0.0001
3—12 weeks 0.922 0.851 0.0001
AUCcrO12 and the CADI was mainly because both indices
350 reflect subsequent immunologic events occurring within the graft.To evaluate this further, we calculated the period from 3 to 8
weeks (AUCr38) post-transplant and correlated this to CADI;
again the correlation was significant (r = 0.748, r2 = 0.560, P =
0.0001). We performed the same analysis to the very end of the
observation period, from 8 to 12 weeks (AUCr812), and again
AUCcr8I2 correlated with the CAD! significantly (r = 0.889, r2
= 0.79, P = 0.0001). However, analysis of the 3 to 12 weeks period(AUCcr312) correlated best with the CADI (r = 0.922, r2 =
0.851, P = 0.0001; Fig. 3b). Thus the extent of the histological
changes of chronic rejection completely depended on the sum of
the intensity and the !ength of the acute rejection episodes as
determined by AUCCr from 3 to 12 weeks (Fig. 4).
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Fig. 2. Scatter diagram relating the Chronic Allograft Damage Index(CADI) to end-point serum creatinine levels in 27 rats three months
post-transplantation. The corresponding regression lines and correlation
coefficients are also shown.
\ 2
U
7 14 21 28 35 42 49 56 63 70 77 84
Day
0
El
U
0
71421283542495663707784
Day
Table 1. Correlations between AUCCr in different time periods and
histopathological end-point CADI
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Fig. 3. Scatter diagrams relating theA UC. during different time periods, (a)
0—3 weeks, (b) 3—12 weeks to the Chronic Allograft Damage Index (CADI).
The corresponding regression lines and correlation coefficients are also
shown (N = 27).
Correlations of A UC,3—12 and acute rejection frequency to CADI
and end-point serum creatinine
Clinical and experimental evidence indicates that the frequency
of acute rejection episodes is the most important single risk factor
for chronic renal allograft rejection. We therefore considered it
important to separately compare both the rejection frequency and
the AUCr312 to CADI and to end-point serum creatinine.
These are depicted in Table 2. AUCr312 correlated better than
the number of rejection episodes both to CAD! (r = 0.922, r2 =
0.845, P = 0.0001, vs. r = 0.876, r2 = 0.767, P = 0.0001) and to
end-point Sr (r = 0.890, r2 = 0.793, P 0.0001, vs. r = 0.811, r2
0.657, P = 0.0001). The result suggests that AUCr312 is
superior to rejection frequency in the prediction of chronic
rejection.
Discussion
Chronic rejection is a complex metabolic disorder. It represents
an allograft response to injury which is accompanied by physio-
logic changes in the graft. Chronic rejection is defined (Kiruna
and Palo Alto consensus conferences) [1, 26] as a permanent
Correlation coefficient
r r2 Pvalue
AUCcr342 vs. CADI 0.922 0.851 0.0001
Number of rejection episodes vs. 0.876 0.767 0.0001
CADI
AUCr312 vs. end-point serum 0.890 0.793 0.0001
creatinine
Number of rejection episodes vs.
end-point serum creatinine 0.811 0.657 0.0001
decline in graft function, with other causes excluded and with
compatible histology on biopsy.
The histological hallmarks of chronic rejection are interstitial
inflammation and fibrosis, glomerular sclerosis, sclerosis of intra-
graft arteries (allograft arteriosclerosis) and tubular atrophy [27,
28], all of which are nonspecific [27, 29—321. We and others have
previously demonstrated that the chronic histological changes in the
allograft can be expressed as a single numerical figure, the
Chronic Allograft Damage Index, CADI [6, 33, 34J.
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Fig. 4. Representative histologic changes of chronic rejection, (a) advanced
glomerular mesangial matrix increase and sclerosis, complete obliteration of
arterioles and severe interstitial inflammation, (b) complete obliteration of
small artePy, severe inflammation and tubular atrophy (periodic acid-Schiff
x300).
Table 2. Correlations between AUC,3-12 and the number of rejection
episodes to CADI and end-point serum crcatinine
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The etiology is multifactorial where both immunologically
nonspecific and specific factors contribute [351. The major immu-
nologically nonspecific etiological factors contributing to chronic
allograft injury, are infection (particularly CMV), advanced donor
age, small graft size, longer cold ischemic times, procurement and
reperfusion injury, and factors contributing to artheoscierosis in
general. The major immunological factors include histoincompat-
ibility, suboptimal immunosuppression, intensity of the anti-allo-
graft response, etc. Previous retrospective human studies [8—111
and our own experimental data [25] clearly indicate that acute
rejection episodes may be the single most important etiological
factor in chronic rejection, and may both initiate and/or exacer-
bate chronic allograft rejection.
Once trauma has been initiated by multiple pathways, chronic
rejection may become independent of the initiating event and the
metabolic changes progress via the mechanisms described under
"response to injury" [36]. When the loss of renal mass reaches a
critical point, adaptive responses to the loss of functioning
nephron mass, such as hyperfiltration of in the remaining neph-
rons as originally postulated by Brenner, Meyer and Hostetter in
1982 [371, will result in an accelerated cycle of mesangial injury
with progressive glomeruler sclerosis following initial damage
[38—41].
Considering the various etiologic factors, both immunologically
specific and nonspecific, it is important to determine the relative
significance of each of them and how they are related. As this is
virtually impossible to determine in humans, we have resorted to
a standardized experimental rat model.
Assuming that the (retrospective) human studies [8—11] are
correct, acute rejection episodes are the primary risk factor for
chronic rejection in human renal transplant recipients. However,
between acute rejection and chronic rejection there might be a
third factor or confounding variable. Such a variable may be
associated with the acute rejection and/or may independently
affect the risk of developing chronic rejection. While the con-
founding factor(s) must be predictive of the occurrence of chronic
rejection, the association need not be causal. Most frequently the
known confounding variables are correlates of another causal
factor, such as acute rejection. For example, tissue incompatibil-
ity, delayed graft function or long cold ischemia time, regrafting,
low dose immunosupression, low CsA bioavailability and high
CsA clearance rates are associated with chronic rejection. Thus
they should be considered as potential confounders of association.
These variables, however, may not be causally related to chronic
rejection but rather act as surrogates of other immonological
factors, particularly acute rejection. Alternatively, these potential
confounding factors may be predictive of chronic rejection inde-
pendently of their association with acute rejection.
In our animal model all known risk factors for chronic rejection
are constant, while we control for our study objects by noting the
frequency, intensity and length of acute rejection episodes. Thus,
in our experimental setting potential confounding variables which
may influence transplant function and/or histology, such as infec-
tions (as CMV), donor age, size incompatibility, cold ischemia
time, technical problems, extent of atherosclerotic disease, etc.,
can be excluded.
Regardless of these highly standardized conditions, there was
still a considerable variation between individual animals in their
renal function during acute rejection episodes, and their response
to intensified immunosuppression. Because of the variability in
the onset, intensity and course of acute rejection episodes and in
their response to treatment, we considered it likely that the impact
on histopathological lesions in chronic rejection might be related
not only to the frequency but also to the intensity and length of
acute rejections. We therefore looked upon a single numerical
parameter, the area under the serum creatinine versus time curve
(AUCcr), to also cover these variables.
We thought that the duration of each episode (in days), the
level of elevation in serum creatinine over normal values (in
tmol/liter) and the efficacy of treatment may all be quantitated by
AUCcr, and that the AUCCr is a more precise measure of the
severity of transplant injury than the rejection frequency. Exper-
imentally this could be tested by using different lengths of
prophylactic immunosuppression, thus creating rejections of dif-
fering intensities and by postponing the first rejection episode to
varying time points after transplantation. By treating rejections
only when creatinine levels rose above 200 tmol/liter, we also
permitted some on-going acute rejections to continue for several
days before treatment was begun. As a quantitative end-point for
chronic rejection we used the histological CADI in addition to
end-point transplant function (5Cr) The perfect positive linear
correlation (r = 0.874, P = 0.0001) between CADI and serum
creatinine measurement (made on the same rats) at three months
increased the reliability of the CADI to quantitate the intensity of
chronic histologic changes relevant to chronic rejection.
There was a perfect positive linear relationship (r = 0.922)
between the AUCr312 and CADI. The power of statistical tests
(P = 0.0001) was too strong to detect an association of the
specified magnitude. As a simultaneously strong (r = 0.890) and
statistically significant (P = 0.0001) positive correlation exists
between AUCr312 and end-point transplant function, a possi-
ble association is suggested between the severity of acute rejection
and chronic rejection. Since the relationship between variables for
chronic rejection was a positive linear relationship, we did not
need to use alternate of transformation such as logarithmic,
reciprocal or square root.
We are aware that the statistically significant correlation be-
tween AUCr312 and CADI does not yet prove that a cause-
and-effect relationship exists between these two parameters. Our
second objective was to judge whether the association between
these two parameters is, in fact, causal. In addition to the
demonstrated association between AUCCr (risk factor; represents
the severity of rejection) and CADI (disease; represents the
chronic rejection) has been identified, several questions must be
answered to strengthen the argument of causality [42].
First, our study is experimental and less subject to bias than
observational (retrospective) study designs (for example, in-
creases in creatinine level caused by reasons other than acute
rejection episodes, such as CsA toxicity, can be excluded) and
favors a causal relationship.
Second, if the causal association is valid, a change in the
frequency and/or intensity of acute rejections should result in a
corresponding change in the intensity of chronic changes as
described by the CADI. In other words there is a dose-response
relationship between the variables. This was indeed the case: the
respective regression relationship was: CADI = 0.45 + [0.001 X
(AUCcr312)1 (r = 0.922, P 0.0001).
Third, our strong and statistically significant (P = 0.0001)
association is likely to represent a cause-and-effect relationship.
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Fourth, evidence for causality is strengthened by the fact that
several clinical investigators using different study designs, which
were mostly case-control and employed genetically outbred pop-
ulations of subjects and different immunosuppressive regimens,
reached the same conclusion [8—111. Graft survival for patients
with none, one or more than one rejection episode showed a
stepwise decrease in eight-year graft survival (deaths with func-
tioning graft censored), which was 83%, 69% and 45%, respec-
tively [11]. Patients with one or more rejection episodes had a risk
ratio of chronic rejection 6.45 times higher than those with no
rejection [11]; in another study the ratio was 7.7 times higher [8].
In these studies the intensity and the length of the rejection
episodes were not considered.
Thus by these restrictions, the frequency, intensity and duration
of acute rejection episodes have been proven as being causal to
chronic rejection. We can at least document that the intensity and
duration of acute rejection episodes correlates with the intensity
of chronic rejection histopathology and to terminal allograft
function.
Strength in our study is that with its experimental design it has
been possible to regulate the intensity of chronic rejection solely
by manipulating the frequency, intensity and length of acute
rejection episodes via selectively administrating and withdrawing
CsA. In any human study design, there will be no such possibility,
not at least when a retrospective study design is employed.
Only one human study exists on the effect of the intensity of
acute rejection episodes on graft survival [43]. The severity of
rejection was assessed from the differences between the lowest
serum creatinine prior to rejection and the highest serum creati-
nine during rejection. The length of acute rejection was not taken
into account. The intensities of serum creatinine alterations were
converted to discrete variables that fell into only a limited number
of separate categories: rejections were considered "mild", "mod-
erate", or "severe", if the AScr was less than 1.6 mg/dl, 1.6 to 3.5
mg/dl or more than 3.5 mg/dl, respectively. Patients with "severe"
acute rejection had the worst prognosis, that is, a 45% one-year
graft survival, while those with "moderate" (70%), and with
"mild" (85%) rejections faired much better. In the absence of
protocol biopsies it was not possible to judge if the kidneys were
really lost to chronic rejection.
Clinical evidence, though less convincing, indicates that the
length of acute rejection may also have an adverse effect on graft
survival. In one study comparing steroids to OKT3 as a primary
anti-rejection drug, OKT3 was significantly more effective than
steroids in reversing acute rejections (94% vs. 75%) [44]. This
advantage was also reflected in a significantly higher one-year
graft survival rate (62% vs. 45%) for patients experiencing
reversible rejection episodes. The standard use of OKT3 has been
limited to rejections unresponsive to steroids. The reversal rates
under such occasions are high (88%), but the end-point of interest
has been the reversal of acute rejection and not long-term graft
survival. Patients rescued from steroid-resistant rejection by
OKT3, had only a 58% one-year graft survival compared to 88%
in steroid-sensitive rejections, and also had significantly worse
renal function [45]. In another independent study, the Ohio group
demonstrated that aggressive treatment with OKT3 as primary
therapy for acute rejection, compared to steroids, results in a 32%
improvement in two-year graft survival [46]. We interpret these
observations to mean that by aggressively treating acute rejection
episodes, both the intensity and the length of each episode can be
reduced to a minimum, with a resultant decrease in chronic
rejection.
Taken together, our results suggest that AUCcr correlates, even
better than the frequency of acute rejection episodes, to chronic
allograft rejection. We believe that the improved correlation is
related to the fact that AUCcI. also takes into account the intensity
and length of acute rejections. We suggest that if the intensity and
length of acute rejections is reduced to a minimum by aggressive
treatment, the long-term graft survival will be improved. How-
ever, this new finding must still be clinically validated.
Reprint requests to Pekka Hayiy, M.D., Ph.D., Transplantation Laboratory,
P.O. Box 21 (Haartmaninkatu 3), FIN 00014 University of Helsinki, Helsinki;
Finland.
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